MannKind (MNKD) Competitors $6.88 +0.02 (+0.29%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MNKD vs. PAHC, ANAB, RDUS, OMER, VNDA, RGEN, MDGL, HALO, IONS, and ALKSShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Phibro Animal Health (PAHC), AnaptysBio (ANAB), Radius Recycling (RDUS), Omeros (OMER), Vanda Pharmaceuticals (VNDA), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), and Alkermes (ALKS). MannKind vs. Phibro Animal Health AnaptysBio Radius Recycling Omeros Vanda Pharmaceuticals Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Phibro Animal Health (NASDAQ:PAHC) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings. Does the media refer more to PAHC or MNKD? In the previous week, MannKind had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 4 mentions for MannKind and 2 mentions for Phibro Animal Health. MannKind's average media sentiment score of 0.38 beat Phibro Animal Health's score of 0.03 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PAHC or MNKD more profitable? MannKind has a net margin of 8.07% compared to Phibro Animal Health's net margin of 1.67%. Phibro Animal Health's return on equity of 21.59% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health1.67% 21.59% 5.85% MannKind 8.07%-17.74%8.68% Do analysts recommend PAHC or MNKD? Phibro Animal Health presently has a consensus price target of $16.50, indicating a potential downside of 29.46%. MannKind has a consensus price target of $8.67, indicating a potential upside of 25.97%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 3 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.25MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders and institutionals hold more shares of PAHC or MNKD? 99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 3.0% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, PAHC or MNKD? Phibro Animal Health has higher revenue and earnings than MannKind. Phibro Animal Health is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.02B0.93$2.42M$0.4354.40MannKind$198.96M9.54-$11.94M$0.0798.29 Which has more volatility and risk, PAHC or MNKD? Phibro Animal Health has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Does the MarketBeat Community believe in PAHC or MNKD? MannKind received 272 more outperform votes than Phibro Animal Health when rated by MarketBeat users. Likewise, 60.12% of users gave MannKind an outperform vote while only 59.73% of users gave Phibro Animal Health an outperform vote. CompanyUnderperformOutperformPhibro Animal HealthOutperform Votes30759.73% Underperform Votes20740.27% MannKindOutperform Votes57960.12% Underperform Votes38439.88% SummaryMannKind beats Phibro Animal Health on 13 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.89B$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio98.2910.57134.3717.77Price / Sales9.54243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book-9.055.474.674.68Net Income-$11.94M$153.61M$119.07M$226.08M7 Day Performance-1.99%-2.00%-1.83%-1.04%1 Month Performance3.93%-7.47%-3.62%1.04%1 Year Performance85.44%31.80%31.63%26.28% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind3.7142 of 5 stars$6.88+0.3%$8.67+26.0%+83.0%$1.89B$198.96M98.29400Insider TradePAHCPhibro Animal Health4.2227 of 5 stars$23.39-1.5%$16.50-29.5%+123.4%$961.95M$1.02B54.401,940Analyst DowngradeANABAnaptysBio2.486 of 5 stars$20.31+1.7%$54.64+169.0%+40.0%$618.03M$17.16M-3.28100RDUSRadius Recycling2.1388 of 5 stars$18.46+5.1%N/A-27.2%$492.65M$2.74B-1.973,011OMEROmeros3.6817 of 5 stars$6.03flat$9.00+49.3%+244.6%$349.44MN/A0.00198Analyst UpgradeVNDAVanda Pharmaceuticals4.4313 of 5 stars$4.90-0.4%$15.50+216.3%+36.9%$286.88M$192.64M0.00203RGENRepligen4.6338 of 5 stars$138.90+8.1%$190.25+37.0%-10.8%$7.20B$638.76M0.001,783Positive NewsMDGLMadrigal Pharmaceuticals3.796 of 5 stars$317.09+0.9%$347.33+9.5%+66.8%$6.85BN/A0.0090Analyst ForecastHALOHalozyme Therapeutics4.9806 of 5 stars$45.76+2.1%$61.11+33.5%+14.4%$5.82B$829.25M15.15390Analyst ForecastIONSIonis Pharmaceuticals4.2197 of 5 stars$35.40+4.9%$60.65+71.3%-28.7%$5.33B$803.07M-14.51800ALKSAlkermes4.7788 of 5 stars$27.91+1.6%$35.42+26.9%+15.4%$4.45B$1.51B14.312,100Positive News Related Companies and Tools Related Companies Phibro Animal Health Alternatives AnaptysBio Alternatives Radius Recycling Alternatives Omeros Alternatives Vanda Pharmaceuticals Alternatives Repligen Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Alkermes Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MNKD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
